Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 18/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29595906 | 1.00 | ATF4 (0.51) | ATF4MAPK1MEN1MAPTKMT2A | |
| SCHEMBL19577376 | 0.91 | ATF4 (0.51) | ATF4MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL19577526 | 0.89 | ATF4 (0.52) | ATF4MEN1MAPTKMT2ASMN1; SMN2 | |
| SCHEMBL19577434 | 0.89 | ATF4 (0.57) | ATF4MEN1KMT2A | |
| SCHEMBL19577407 | 0.87 | ATF4 (0.55) | ATF4 | |
| SCHEMBL19577485 | 0.86 | ATF4 (0.55) | ATF4MEN1KMT2A | |
| SCHEMBL21116582 | 0.85 | ATF4 (0.52) | ATF4 | |
| SCHEMBL30445532 | 0.84 | ATF4 (0.58) | ATF4KMT2A | |
| SCHEMBL19577471 | 0.84 | ATF4 (0.58) | ATF4KMT2A | |
| SCHEMBL24324520 | 0.84 | ATF4 (0.47) | ATF4MAPK1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210393599-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2021-12-23 | — | — | US | disclosed |
| US-10836725-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| WO-2017193041-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836725-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | ATF4 1/4885MAPK1 239/4885MEN1 4714/4885 |
| US-20210393599-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885MAPK1 239/4885MEN1 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.